Description
Ensartinib is a targeted therapy currently being studied in clinical trials for certain types of cancer, including colorectal cancer. It is being investigated in early-phase trials (Phase 1 and Phase 2) to see if it is safe and effective. These trials are looking at patients whose tumors have specific genetic changes (mutations) like ALK, ATM, BRAF, BRCA1, BRCA2, or EGFR (T790M). It is often studied in combination with other targeted therapies. The goal is to see if ensartinib can help control or shrink tumors in patients with these specific genetic alterations.
Mechanism of Action
Ensartinib is designed to target specific proteins within cancer cells that are involved in tumor growth and survival. The specific molecular target of ensartinib is being characterized in clinical trials. It is believed to interfere with signaling pathways that cancer cells rely on, potentially slowing down their growth or causing them to die. It is being studied in patients whose tumors have specific genetic mutations that might make them sensitive to this type of targeted therapy.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.